Drug
ocrelizumab and hyaluronidase
Marketed as OCREVUS ZUNOVO.
Generic name
ocrelizumab and hyaluronidase
Brand names
OCREVUS ZUNOVO
First FDA approval
2024-09-13
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761371 | OCREVUS ZUNOVO | 2024-09-13 | GENENTECH INC |
Manufacturers
GENENTECH INC
Frequently asked questions
When was ocrelizumab and hyaluronidase FDA approved?
Earliest FDA approval on record: 2024-09-13.
What brand names are sold as ocrelizumab and hyaluronidase?
OCREVUS ZUNOVO.
Sources
Appeal a ocrelizumab and hyaluronidase denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com